tbuckley/cabot-search huggingface dataset:
Genomic profiling of breast cancer in African American women.
Authors: Raquel Nunes, Lynette Wray, Mihriye Mete, Thomas Godwin, Pia Maarit Herbolsheimer, Lana Bijelic, Marc E. Boisvert, Sandra M. Swain
Journal: Journal of Clinical Oncology (2014)

11067 Background: Molecular profiling of breast cancer (BC) identifies intrinsic subtypes with distinct gene expression and clinical characteristics. In the US, BC is less frequent in African-American females (AAF); however mortality is higher, particularly among younger women. Methods: Gene expression in tumors from AAF presenting with early stage or locally advanced BC was evaluated using the Symphony platform on fresh and paraffin-embedded tissue (Agendia inc), a microarray-based method which classifies tumors according to prognosis (MammaPrint, MP), molecular subtype (BluePrint, BP) and estrogen receptor (ER), progesterone receptor (PR) and Human Epidermal Growth Factor Receptor 2 (HER2) mRNA levels (TargetPrint, TP). Genomic information is correlated with clinical and pathologic characteristics and Oncotype DX recurrence score (RS) when available. Patients (pts) will be followed for 5 years. Results: Results are available in 88 pts, with 12 pending for an accrual goal of 100. Median age 60 years (range 22-98), 37 stage I, 36 stage II, 15 stage III disease. 67% of pts had High Risk (HR) MP. Age ≤ 40 and grade were significantly associated with HR MP (p=0.022 and < 0.0001, respectively), while stage was not. 20 cancers were triple negative (TN) by IHC;18 of these were Basal-type and 1 HER2-type (1 not evaluable). In the 10 cases ER positive by IHC but negative by TP, 5 were Basal-type and 5 were HER2-type. Of the 12 pts HER2 positive by IHC/FISH, 4 were Luminal-type and 1 was Basal-type; none of these was HER2 positive by TP. 24 pts had Oncotype RS results: 2 were HR both by Oncotype and MP; 5 had intermediate RS, 3 were HR by MP; 17 had a low RS, 8 of which were HR by MP and Luminal-type by BP. Conclusions: AAF with stage I to III BC often present with High Risk disease, particularly at younger ages and irrespective of stage. Molecular subtyping confirmed the biologic heterogeneity in TN, HER2 positive and ER positive tumors. Oncotype RS and MP offered different prognostic information. Follow up will be needed to determine correlation with outcome. Funding: MP, BP and TP test provided by Agendia. Biostatistical support by GHUTTCS-CTSA. BP MP ER/PR positive HER2 positive Low risk (n=29/32%) High risk (n=59/67%) IHC TP IHC/FISH TP Luminal 29 25 54 54 4 0 Basal 0 25 5 0 1 0 HER2 0 8 5 0 7 7
TWENTY YEARS OF HILL-BURTON
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Genome Politics
Authors: James Tabery, Lisa Parker
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Priming of circulating human eosinophils following late response to allergen challenge
Authors: DJ Evans, MA Lindsay, BJ O'Connor, PJ Barnes
Journal: European Respiratory Journal (1996)

The eosinophil is recognized as an important effector cell in asthma. To investigate the role of eosinophils in the aetiology of asthma, we have examined whether peripheral blood eosinophils are primed following whole-lung allergen challenge. Nineteen mild asthmatics, who each demonstrated a late asthmatic response (LAR), were studied. The priming of eosinophils following allergen challenge was assessed by measuring: 1) platelet-activating factor (PAF) and complement factor 5a (C5a) stimulated H2O2 release upon fibrinogen-coated tissue culture plates (n = 8); and 2) ex-vivo cell survival (n = 11). Subjects were venepunctured before and 24 h after allergen challenge and eosinophils were prepared by immunomagnetic separation. Basal H2O2 release was increased from eosinophils following allergen challenge. The response to PAF stimulation was significantly increased in terms of cell sensitivity (negative log of concentration producing half the maximal effect (pD2)) and responsiveness (maximum effect Emax). With C5a, although there was no change in sensitivity there was a significant increase in the maximal response. Ex-vivo eosinophil survival (at 3 days and cell half-life) was significantly prolonged following allergen challenge. In conclusion, we have demonstrated the priming of circulating eosinophils following allergen challenge.
Antidotes Against Curare in Anesthesia: Experience with Galanthamine
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Against the Odds: Blacks in the Profession of Medicine in the United States
Authors: Vera B. Thurmond
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FRI0174 A population based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality
Authors: C Hyldgaard, O Hilberg, AB Pedersen, SP Ulrichsen, A Løkke, E Bendstrup, T Ellingsen
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Interstitial lung disease (ILD) is an important reason for excess mortality among patients with rheumatoid arthritis. <h3>Objectives</h3> The aim of this study was to compare mortality risks in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and patients with RA without ILD. <h3>Methods</h3> The study was conducted in Denmark, using nationwide, prospectively collected data from the national medical registries. Among patients with RA, diagnosed between 2004 and 2016, 679 patients with RA-ILD were matched for age, gender, and age at RA diagnosis with 11,722 patients with RA but without ILD. Mortality risks were assessed using Kaplan-Meier survival curves, and hazard rate ratios (HRR) for death were estimated using Cox proportional hazards regression models. <h3>Results</h3> The number of prevalent RA patients more than doubled from 15,352 to 35,362 individuals during the study period. RA-ILD was seen in 2.2% of incident RA patients. 34.0% of RA-ILD cases were diagnosed within one year prior to and one year after the RA diagnosis. One-year mortality was 13.9% in RA-ILD and 3.8% in non-ILD RA, three-year mortality was 28.0% and 10.9%, and five-year mortality was 39.0% and 18.2%, respectively. The HRRs for death were two to 10 times increased for RA-ILD compared with non-ILD RA, irrespective of follow-up period. Stratified analysis showed that the HRR for death was highest in the first months after the diagnosis of RA-ILD was made, especially in patients diagnosed with RA before diagnosis of ILD. HRR was higher in males and in patients without comorbidity as assessed by the Charlson Comorbidity Index. <h3>Conclusions</h3> ILD is a serious complication in RA with a significantly increased mortality compared with a large matched cohort of RA comparisons without ILD. <h3>Disclosure of Interest</h3> None declared
Prospective payment system and impairment at discharge. The 'quicker-and-sicker' story revisited
Authors: J. Kosecoff
Journal: JAMA (1990)

Since the introduction of the prospective payment system (PPS), anecdotal evidence has accumulated that patients are leaving the hospital "quicker and sicker." We developed valid measures of discharge impairment and measured these levels in a nationally representative sample of patients with one of five conditions prior to and following the PPS implementation. Instability at discharge (important clinical problems usually first occurring prior to discharge) predicted the likelihood of postdischarge deaths. At 90 days postdischarge, 16% of patients discharged unstable were dead vs 110% of patients discharged stable. After the PPS introduction, instability increased primarily among patients discharged home. Prior to the PPS, 10% of patients discharged home were unstable; after the PPS was implemented, 15% were discharged unstable, a 43% relative change. Efforts to monitor the effect of this increase in discharge instability on health should be implemented. (<i>JAMA</i>. 1990;264:1980-1983)
Turning free speech into commercial speech: Philip Morris' use of journalists to discredit the EPA report on secondhand smoke
Authors: R. D. Hurt, M. E. Muggli, L. B. Becker
Journal: Journal of Clinical Oncology (2004)

6151 Background: Tobacco company documents show that it launched a multifaceted effort to influence journalists in the scientific debate about the harmful effects of secondhand smoke in order to derail the risk assessment on environmental tobacco smoke. Methods: Searches of previously secret internal tobacco industry documents were conducted on-line and at the Minnesota Tobacco Document Depository. Lexis-Nexis was used to locate news stories written by the journalists cited in this paper. Results: To address a potential backlash in public opinion from the 1992 EPA risk assessment, Philip Morris used its public relations firm Burson Marsteller to “build considerable reasonable doubt… particularly among consumers” about the “scientific weaknesses” of the report. Media and political consultant Richard Hines was a key player in carrying out “EPA bashing” for Philip Morris. Steve Parrish, vice president at Philip Morris wrote, “Richard is responsible for a number of articles that have appeared in…major news publications regarding EPA and ETS.” Philip Morris expanded its journalist network by creating a school of journalism through the National Journalism Center (NJC) and planned to “design innovative strategies to communicate our position on ETS through education programs targeting policy makers and the media.” NJC was to “train budding journalists in free market political and economic principles” and was financially supported by Philip Morris. Conclusions: This is the first report to show the extent to which the tobacco industry has gone to influence the print media on the health effects of secondhand smoke. Journalists can fall victim to well orchestrated public relations efforts regardless of their scientific validity. More scrutiny is warranted by professional media organizations that oversee the ethical conduct of their members. Supported by R01 CA90791 “Tobacco Industry Documents on ETS -The Next Front” No significant financial relationships to disclose.
Infant Mortality
Authors: Charles B. Pender
Journal: JAMA (1971)

<h3>To the Editor.—</h3> In reference to Balfe's editorial<sup>1</sup>and letter<sup>2</sup>on infant death rates, a significant but not-well-recognized fact must be pointed out. This is an observation made from an American government publication<sup>3</sup>in which there is a comparison of infant mortality in the United States between whites and nonwhites for the years 1935 to 1964. The comparisons are graphically presented in the following four groups: (1) in the first 24 hours of life, (2) 1 to 6 days of age, (3) 7 to 27 days of age, and (4) 28 days to 11 months of age. The mortality in all four groups declined during this period. The "difference" between mortality of whites and nonwhites in groups 2, 3, and 4 "decreased markedly" during this period. However, the "difference" in group 1 (first 24 hours of life) had more than "quadrupled" during the same period (ie, from
Authors' reply
Authors: A. A M E Stenger, P. M Houtman, G. A W Bruyn
Journal: Annals of the Rheumatic Diseases (1993)

Have a career related problem that needs answering? Can9t find the person to point you in the right direction? Log on to the Advice Zone for reliable medical careers advice. You can post a question or see if one of our 300 advisers has already answered a similar question. Here is a selection of questions and answers posted on the site <b>www.bmjcareers.com/advicezone</b>
Handyperson's Hazard: Crawl Space Sporotrichosis
Authors: Paul F. Lehmann
Journal: JAMA (1995)

<h3>To the Editor.</h3> —Cutaneous sporotrichosis in the United States is associated with outdoor activities and typically follows traumatic injury with concurrent exposure to<i>Sporothrix schenckii</i>in sphagnum moss or thorny plants.<sup>1</sup>We report three cases in which each patient contracted the disease while working in the same crawl space. The first was a 37-year-old man who, in December 1993, had been working in a crawl space under his house in Indiana. Three days later, he noticed "bumps" that, despite antibacterial therapies, developed within 10 weeks into an inflamed verrucous plaque on the wrist (Figure 1, for example) and into ulcerated lesions accompanied by multiple nodules along the lymphatics on his face. His 33-year-old wife, who had worked in the crawl space in January 1994, developed a lesion at the site of a recent cat scratch on her thumb. Five weeks later, this lesion ulcerated, and several erythematous nodules were
Should physicians boycott airlines that permit smoking?
Authors: P. A. Goodwin
Journal: JAMA (1989)

<h3>In Reply.—</h3> Concerning the comments of Mr Jones, the intention of the study was not to demonstrate the hazardous nature of passive smoke exposure, which has been amply documented elsewhere.<sup>1,2</sup>Our study demonstrated exposure during the flight to cigarette smoke, which was absorbed and later excreted in the form of cotinine, a metabolite of nicotine. Furthermore, both the degree of exposure to nicotine and the levels of cotinine subsequently excreted were correlated with symptoms of physical irritation as well as annoyance. Second, the purpose of measuring nicotine in the air was because it is a marker of exposure to cigarette smoke. It was not to imply that particular levels of nicotine per se are deleterious. Environmental tobacco smoke contains several thousand chemicals, of which at least 40 are demonstrated carcinogens. These carcinogens are the species of interest for risk-assessment studies. Third, although health information on environmental tobacco smoke is
Hormone replacement therapy (HRT) in women with previously treated primary breast cancer. Update XIV
Authors: A. Z. Bluming
Journal: Journal of Clinical Oncology (2008)

20693 Background: To assess the incidence of contralateral or recurrent breast cancer among women prospectively treated with HRT after initial breast cancer diagnosis. Methods: A community-based, prospective, single-arm, pilot study of HRT among 248 women with previously treated primary breast cancer. Results: Median duration of HRT is 90+ months (range 12+ -185+). Median interval from last menses to initiation of HRT is 120 months (range 2–612). Median interval from initial surgery to initiation of HRT is 50 months (range 2–361 months). One hundred and twenty two patients have stopped HRT (49%), 60 because of anxiety about taking HRT (24%), 50 because of breast cancer development (20%), 5 because of the development of non-breast cancers, 2 died of nonmalignant disease, 3 because of HRT-associated symptoms, and 2 because of hypercoagulability. CHRT, as opposed to ERT, was administered to 50% of all patients and 58% of the 50 who subsequently developed breast cancer on study. Actuarial DFS to 25 years for T1N0 patients was 67% versus 35% (DSS=86%) for comparable T1N0 patients who did not receive HRT. Conclusions: No evidence to date of increased development, recurrence or of breast cancer-related death associated with post diagnosis HRT. Actuarial disease-free survival (DFS), disease-specific survival (DSS), and median duration of HRT Stage Pt # DFS DSS HRT mos T0N0 72 78%* 100% 95+ T1N0 117 66%** 90% 96+ T2N0 19 75%*** 92% 76+ T1N1 28 58%**** 86% 72+ T2–3N1 12 64%***** 69% 70 All Patients 248 61% 88% 90+ * T0N0: 2 LCIS recurred locally after lumpectomy alone; 3 DCIS recurred locally after lumpectomy/RT; 5 contralateral tumors (3 DCIS, 2 T1N0); 1 distant recurrence - liver. (alive 4.5 years later); ** T1N0: 9 local recurrences after lumpectomy/RT; 7 contralateral tumors; 8 distant recurrences - 3 lung, 2 liver, 3 bone - 4 died; *** T2N0: 2 local recurrences after lumpectomy/RT; 2 distant recurrences - lung - 1 died; **** T1N1: 3 local recurrence after lumpectomy/RT; 2 contralateral tumors; 2 distant recurrences - 1 bone, 1 supraclav node - 2 died; ***** T2–3N1: 1 contralateral tumor: 3 distant recurrences - 1 cerv node-2 bone mets - 3 died. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Wyeth
Haitian Humanity
Authors: Charles K. Morris
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Over Espresso
Authors: Sheri DeFord
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal